Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIA-2291 in Patients After an Acute Coronary Syndrome Event
NCT00358826Phase 2Completed
- Sponsor
- Tallikut Pharmaceuticals, Inc.
- Start
- Jul 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Atreleuton in coronary artery disease (CAD) (4 arms), sponsored by Tallikut Pharmaceuticals, Inc. Primary endpoint: Change From Baseline on ex Vivo Leukotriene B4 Synthesis in Whole Blood at 12 weeks. Started Jul 2006; status: completed.
02
Drugs
Atreleuton
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00358826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00358826.